Advertisement
Advertisement

IRWD

IRWD logo

Ironwood Pharmaceuticals, Inc. - Class A

4.57
USD
Sponsored
+0.12
+2.65%
Feb 06, 16:00 UTC -5
Closed
exchange

After-Market

4.76

+0.20
+4.31%

IRWD Earnings Reports

Positive Surprise Ratio

IRWD beat 21 of 39 last estimates.

54%

Next Report

Next Week
Date of Next Report
Feb 12, 2026
Estimate for Q4 25 (Revenue/ EPS)
$51.95M
/
$0.04
Implied change from Q3 25 (Revenue/ EPS)
-57.44%
/
-83.33%
Implied change from Q4 24 (Revenue/ EPS)
-42.62%
/
+100.00%

Ironwood Pharmaceuticals, Inc. - Class A earnings per share and revenue

On Nov 10, 2025, IRWD reported earnings of 0.24 USD per share (EPS) for Q3 25, beating the estimate of 0.10 USD, resulting in a 135.29% surprise. Revenue reached 122.06 million, compared to an expected 76.20 million, with a 60.19% difference. The market reacted with a +31.77% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 51.95 million USD, implying an decrease of -83.33% EPS, and decrease of -57.44% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Ironwood Pharmaceuticals, Inc. - Class A reported EPS of $0.24, beating estimates by 135.29%, and revenue of $122.06M, 60.19% above expectations.
The stock price moved up 31.77%, changed from $1.92 before the earnings release to $2.53 the day after.
The next earning report is scheduled for Feb 12, 2026.
Based on 6 analysts, Ironwood Pharmaceuticals, Inc. - Class A is expected to report EPS of $0.04 and revenue of $51.95M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement